<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528047</url>
  </required_header>
  <id_info>
    <org_study_id>PRLX93936-0001</org_study_id>
    <nct_id>NCT00528047</nct_id>
  </id_info>
  <brief_title>Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Multi-center, Open-Label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of PRLX 93936 Administered Intravenously Daily for Five Days Followed by a 23-Day Rest Period in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prolexys Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prolexys Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of PRLX 93936 and see what kind of effect it&#xD;
      has on patients and their cancer. This study will also determine the highest dose of PRLX&#xD;
      93936 that can be given without causing adverse side effects and the dose of PRLX 93936 that&#xD;
      should be used in future studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the safety, pharmacokinetics, and pharmacodynamics of PRLX 93936&#xD;
      administered intravenously over 1 hr daily for 5 days in patients with advanced solid tumors.&#xD;
      Patients will be evaluated prior to dosing, during dosing and following dosing, on a 28-day&#xD;
      cycle. Tumor response will be evaluated every other cycle.&#xD;
&#xD;
      Three patients will be assigned per dose level until the Maximum Tolerated Dose (MTD) is&#xD;
      reached or a a Dose-Limited Toxicity (DLT) is encountered. Sequential cohorts of three&#xD;
      patients will be treated with escalating doses until the Maximum Tolerated Dose (MTD) is&#xD;
      reached.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Daily during dosing, then weekly during followup</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms (ECGs)</measure>
    <time_frame>Multiple times during dosing, then weekly during followup</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Echocardiograms (ECHO)</measure>
    <time_frame>Baseline and every other cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor assessment</measure>
    <time_frame>Baseline and every other cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sampling for pharmacokinetics</measure>
    <time_frame>Days 1 and 5 of dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>PRLX 93936</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRLX 93936</intervention_name>
    <description>PRLX 93936 will be administered intravenously over one hour daily for 5 days.</description>
    <arm_group_label>PRLX 93936</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumors&#xD;
&#xD;
          -  Tumor progression after receiving standard/approved chemotherapy and for whom no&#xD;
             available treatment provides clinical benefit&#xD;
&#xD;
          -  One or more metastatic tumors measurable on a CT scan or MRI per RECIST criteria&#xD;
&#xD;
          -  ECOG performance 0-1&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Age &gt;/= 18 years&#xD;
&#xD;
          -  A negative pregnancy test (if female of child-bearing potential)&#xD;
&#xD;
          -  Acceptable liver function:&#xD;
&#xD;
          -  Bilirubin &lt;/= 1.5 times the Upper Limit of Normal (ULN)&#xD;
&#xD;
          -  AST (SGOT), ALT (SGPT) and Alkaline phosphatase &lt;/= 2.5 times ULN (if liver metastases&#xD;
             are present, then &lt;/= 5 times ULN is allowed)&#xD;
&#xD;
          -  Acceptable renal function:&#xD;
&#xD;
          -  Serum creatinine within normal limits, OR calculated creatinine clearance &gt;/= 60&#xD;
             mL/min/1.73m2 for patients with creatinine levels above institutional normal&#xD;
&#xD;
          -  Acceptable hematologic status:&#xD;
&#xD;
          -  Granulocyte count &gt;/= 1500 cells/mm3&#xD;
&#xD;
          -  Platelet count &gt;/= 100,000 (plt/mm3)&#xD;
&#xD;
          -  Hemoglobin &gt;/= 9.0 g/dL&#xD;
&#xD;
          -  Urinalysis: no clinically significant abnormalities&#xD;
&#xD;
          -  Acceptable coagulation status:&#xD;
&#xD;
          -  PT within normal limits&#xD;
&#xD;
          -  aPTT within normal limits&#xD;
&#xD;
          -  Completed any chemotherapy, major surgery, or irradiation at least four weeks before&#xD;
             enrollment in this study (six weeks for mitomycin-C or nitrosoureas, and two weeks for&#xD;
             &quot;targeted&quot; therapies such as kinase inhibitors). Patient must have recovered from all&#xD;
             toxicities incurred as a result of previous therapy.&#xD;
&#xD;
          -  QT intervals of QTC &lt;/= 450 msec for men and &lt;/= 470 msec for women (as measured by&#xD;
             Hodges equation)&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt;/= 50% by 2D Echocardiogram (or &gt; institutional&#xD;
             lower limits of normal)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NYHA Class III or IV, cardiac disease, myocardial infarction within the past six&#xD;
             months, unstable arrhythmia, or evidence of ischemia on ECG&#xD;
&#xD;
          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             therapy&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy&#xD;
             within four weeks prior to study entry (six weeks for mitomycin-C or nitrosoureas and&#xD;
             two weeks for targeted therapies such as kinase inhibitors).&#xD;
&#xD;
          -  Unwillingness or inability to comply with protocol procedures&#xD;
&#xD;
          -  Known current infection with HIV, hepatitis B or hepatitis C&#xD;
&#xD;
          -  Currently receiving any other investigational agent&#xD;
&#xD;
          -  Currently receiving medications metabolized by the cytochrome P450 3A4 enzyme pathway&#xD;
&#xD;
          -  Presence of clinically apparent central nervous system metastases or carcinomatous&#xD;
             meningitis. Patients with brain metastases which are well controlled (patients not&#xD;
             taking dexamethasone or anti-seizure medication &gt;/= three months after treatment) may&#xD;
             be enrolled.&#xD;
&#xD;
          -  Any other severe concurrent disease, which in the judgement of the investigator would&#xD;
             make the patient inappropriate for the study&#xD;
&#xD;
          -  Diagnosis of hypertension&#xD;
&#xD;
          -  Previously enrolled in this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Von Hoff, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>TGen Clinical Research Services at Scottsdale Healthcare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter J. Rosen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tower Cancer Research Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Wagner, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TGen Clinical Research Services at Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tower Cancer Research Foundation</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>September 7, 2007</study_first_submitted>
  <study_first_submitted_qc>September 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2007</study_first_posted>
  <last_update_submitted>January 3, 2012</last_update_submitted>
  <last_update_submitted_qc>January 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Neoplasm, Malignant</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

